• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

定量分析 CAR-T 治疗后中国 B 细胞急性淋巴细胞白血病患者 T 细胞受体库改变。

Quantitative characterization of T-cell repertoire alteration in Chinese patients with B-cell acute lymphocyte leukemia after CAR-T therapy.

机构信息

Bone Marrow Transplantation Center, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.

Institute of Hematology, Zhejiang University, Hangzhou, China.

出版信息

Bone Marrow Transplant. 2019 Dec;54(12):2072-2080. doi: 10.1038/s41409-019-0625-y. Epub 2019 Aug 5.

DOI:10.1038/s41409-019-0625-y
PMID:31383996
Abstract

Chimeric antigen receptor (CAR) T-cell therapy has displayed potent anti-leukemia activity in acute lymphocytic leukemia (ALL), acting as a new ray of hope to refractory/relapsed patients. However, the influence of CAR-T therapy on host immune system has not been well elucidated. Thus, We applied high-throughput T cell receptor β chain sequencing to track the dynamic change of T-cell repertoire induced by CAR-T therapy in B-cell ALL patients. Six Chinese patients achieving complete remission were under observation, whose blood samples, bone marrow samples and infused CAR-T samples were collected at serial time points before and after CAR-T therapy. We observed decreased TCR diversity and increased clonality of T-cell repertoire in both peripheral blood and bone marrow after CAR-T administration. The persistent T cell clones in blood and bone marrow expanded following leukemic cell destruction and were barely detected in CAR T-cell pool. For the first time, our results demonstrated CAR-T therapy could stimulate the clonal proliferation of CAR-negative T cells in patients. Considering other groups' animal results indicating that CAR-T therapy could facilitate the proliferation of tumor antigen-specific T cells and that the emergence of these T cell clones followed the destruction of leukemic cells, they are most likely tumor antigen-specific.

摘要

嵌合抗原受体 (CAR) T 细胞疗法在急性淋巴细胞白血病 (ALL) 中显示出强大的抗白血病活性,为难治/复发患者带来了新的希望。然而,CAR-T 疗法对宿主免疫系统的影响尚未得到充分阐明。因此,我们应用高通量 T 细胞受体β链测序来跟踪 CAR-T 疗法在 B 细胞 ALL 患者中诱导的 T 细胞 repertoire 的动态变化。我们观察到在 CAR-T 给药后,外周血和骨髓中的 TCR 多样性降低,T 细胞 repertoire 的克隆性增加。在白血病细胞破坏后,血液和骨髓中持续存在的 T 细胞克隆扩增,而在 CAR-T 细胞池几乎检测不到。我们的研究结果首次表明,CAR-T 疗法可以刺激患者中 CAR 阴性 T 细胞的克隆增殖。考虑到其他研究小组的动物实验结果表明,CAR-T 疗法可以促进肿瘤抗原特异性 T 细胞的增殖,并且这些 T 细胞克隆的出现紧随白血病细胞的破坏,它们很可能是肿瘤抗原特异性的。

相似文献

1
Quantitative characterization of T-cell repertoire alteration in Chinese patients with B-cell acute lymphocyte leukemia after CAR-T therapy.定量分析 CAR-T 治疗后中国 B 细胞急性淋巴细胞白血病患者 T 细胞受体库改变。
Bone Marrow Transplant. 2019 Dec;54(12):2072-2080. doi: 10.1038/s41409-019-0625-y. Epub 2019 Aug 5.
2
A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia.新型第 1928zT2 CAR T 细胞可诱导急性淋巴细胞白血病髓外复发缓解。
J Hematol Oncol. 2018 Feb 20;11(1):25. doi: 10.1186/s13045-018-0572-x.
3
Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy.在接受鼠源 CD19 CAR-T 治疗后复发或失败的复发/难治性 B-ALL 患者中使用人源化 CD19 CAR-T 细胞。
BMC Cancer. 2022 Apr 12;22(1):393. doi: 10.1186/s12885-022-09489-1.
4
CD4CD25CD127 regulatory T cells associated with the effect of CD19 CAR-T therapy for relapsed/refractory B-cell acute lymphoblastic leukemia.CD4CD25CD127 调节性 T 细胞与 CD19 CAR-T 治疗复发/难治性 B 细胞急性淋巴细胞白血病的疗效相关。
Int Immunopharmacol. 2021 Jul;96:107742. doi: 10.1016/j.intimp.2021.107742. Epub 2021 May 11.
5
Evidence of long-lasting anti-CD19 activity of engrafted CD19 chimeric antigen receptor-modified T cells in a phase I study targeting pediatrics with acute lymphoblastic leukemia.在一项针对小儿急性淋巴细胞白血病的 I 期研究中,证明了移植的嵌合抗原受体修饰的 CD19 特异性 T 细胞具有持久的抗 CD19 活性。
Hematol Oncol. 2019 Dec;37(5):601-608. doi: 10.1002/hon.2672. Epub 2019 Sep 15.
6
Donor-derived CAR-T Cells Serve as a Reduced-intensity Conditioning Regimen for Haploidentical Stem Cell Transplantation in Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: Case Report and Review of the Literature.供体来源的 CAR-T 细胞作为减轻强度预处理方案,用于治疗复发/难治性急性淋巴细胞白血病的单倍体相合干细胞移植:病例报告及文献复习。
J Immunother. 2018 Jul/Aug;41(6):306-311. doi: 10.1097/CJI.0000000000000233.
7
Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia.半相合CD19嵌合抗原受体T细胞与干细胞共同输注在难治性急性淋巴细胞白血病中实现了完全供者植入。
J Hematol Oncol. 2016 Nov 25;9(1):131. doi: 10.1186/s13045-016-0357-z.
8
Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia.新型抗 CD19 嵌合抗原受体构建的 CD19 CAR T 在复发或难治性急性淋巴细胞白血病中的疗效和安全性。
J Hematol Oncol. 2020 Sep 7;13(1):122. doi: 10.1186/s13045-020-00953-8.
9
Potent anti-leukemia activities of humanized CD19-targeted Chimeric antigen receptor T (CAR-T) cells in patients with relapsed/refractory acute lymphoblastic leukemia.在复发/难治性急性淋巴细胞白血病患者中,人源化 CD19 靶向嵌合抗原受体 T(CAR-T)细胞具有强大的抗白血病活性。
Am J Hematol. 2018 Jul;93(7):851-858. doi: 10.1002/ajh.25108. Epub 2018 Apr 28.
10
Kinetics of immune reconstitution after anti-CD19 chimeric antigen receptor T cell therapy in relapsed or refractory acute lymphoblastic leukemia patients.抗 CD19 嵌合抗原受体 T 细胞治疗复发或难治性急性淋巴细胞白血病患者后的免疫重建动力学。
Int J Lab Hematol. 2021 Apr;43(2):250-258. doi: 10.1111/ijlh.13375. Epub 2020 Oct 28.

引用本文的文献

1
Not just a combination: a fully-integrated strategy of cellular therapy for acute myeloid leukemia expressing CD7, a heretofore elusive target.不仅仅是一种组合:针对表达CD7的急性髓系白血病的细胞治疗的完全整合策略,CD7是一个此前难以捉摸的靶点。
Sci China Life Sci. 2025 Apr;68(4):1202-1204. doi: 10.1007/s11427-024-2711-y. Epub 2024 Dec 20.
2
Insights into cytomegalovirus-associated T cell receptors in recipients following allogeneic hematopoietic stem cell transplantation.异基因造血干细胞移植后受者巨细胞病毒相关 T 细胞受体的研究进展。
Virol J. 2024 Sep 30;21(1):236. doi: 10.1186/s12985-024-02511-x.
3
Neutrophil activation and clonal CAR-T re-expansion underpinning cytokine release syndrome during ciltacabtagene autoleucel therapy in multiple myeloma.
中性粒细胞激活和克隆 CAR-T 再扩增是多发性骨髓瘤患者 cilta-cabtagene autoleucel 治疗中细胞因子释放综合征的基础。
Nat Commun. 2024 Jan 8;15(1):360. doi: 10.1038/s41467-023-44648-3.
4
T-cell receptor sequencing reveals hepatocellular carcinoma immune characteristics according to Barcelona Clinic liver cancer stages within liver tissue and peripheral blood.T 细胞受体测序揭示了巴塞罗那临床肝癌分期在肝组织和外周血中根据肝癌分期的肝癌免疫特征。
Cancer Sci. 2024 Jan;115(1):94-108. doi: 10.1111/cas.16013. Epub 2023 Nov 14.
5
Multidisciplinary recommendations for the management of CAR-T recipients in the post-COVID-19 pandemic era.COVID-19大流行后时代CAR-T细胞疗法接受者管理的多学科建议。
Exp Hematol Oncol. 2023 Jul 27;12(1):66. doi: 10.1186/s40164-023-00426-x.
6
Immune repertoire analysis of normal Chinese donors at different ages.正常中国供体不同年龄的免疫受体谱分析。
Cell Prolif. 2022 Nov;55(11):e13311. doi: 10.1111/cpr.13311. Epub 2022 Aug 4.
7
The Relationship Between Convergent IGH Signatures and Severity of COVID-19 Patients by Next-Generation Sequencing of B-Cell Repertoire.通过B细胞受体组的下一代测序分析COVID-19患者中趋同IGH特征与疾病严重程度的关系
Front Microbiol. 2022 Feb 9;12:833054. doi: 10.3389/fmicb.2021.833054. eCollection 2021.
8
Altered T-Cell Receptor β-Chain and Lactate Dehydrogenase Are Associated With the Immune Pathogenesis of Biliary Atresia.T细胞受体β链和乳酸脱氢酶的改变与胆道闭锁的免疫发病机制相关。
Front Med (Lausanne). 2021 Dec 24;8:778500. doi: 10.3389/fmed.2021.778500. eCollection 2021.
9
The methods and advances of adaptive immune receptors repertoire sequencing.适应性免疫受体谱测序的方法和进展。
Theranostics. 2021 Aug 19;11(18):8945-8963. doi: 10.7150/thno.61390. eCollection 2021.
10
Allogeneic CAR Invariant Natural Killer T Cells Exert Potent Antitumor Effects through Host CD8 T-Cell Cross-Priming.同种异体嵌合抗原受体不变自然杀伤 T 细胞通过宿主 CD8 T 细胞交叉呈递发挥强大的抗肿瘤作用。
Clin Cancer Res. 2021 Nov 1;27(21):6054-6064. doi: 10.1158/1078-0432.CCR-21-1329. Epub 2021 Aug 10.